Pharming Group N.V.PHAR
What Pharming Group N.V. does.
Pharming Group is a global biotechnology company that develops and commercializes innovative therapies for rare and ultra-rare diseases with significant unmet need. We focus on immunological and genetic conditions where our scientific and commercial expertise can help advance care over the long term.
Patients are at the heart of everything we do. Their insights along with those of caregivers and the scientific community shape our strategy, guide our clinical study designs, and influence how we manage our approved therapies.
Our teams combine deep scientific, medical, and operational expertise in rare disease drug development and commercialization. We leverage proven and efficient clinical development, supply chain, and commercial infrastructure to advance and expand our portfolio and pipeline and increase access for patient communities that currently lack adequate treatment options.
Revenue and profit, by fiscal year.
| Fiscal year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Revenue | $212.2M | $198.9M | $205.6M | $245.3M | $297.2M | $376.1M |
| Net income | $37.7M | $16.0M | $13.7M | -$10.5M | -$11.8M | $2.9M |
| Free cash flow | $79.0M | $27.1M | $21.1M | -$18.7M | -$2.6M | $54.0M |
More on PHAR.
- Pharming Group N.V. summary
- Pharming Group N.V. financial statements
- Pharming Group N.V. key metrics
- Pharming Group N.V. health scores and style box
- Pharming Group N.V. earnings
- Pharming Group N.V. dividends
- Pharming Group N.V. valuation
- Pharming Group N.V. ownership and insiders
- Pharming Group N.V. peers
Figures from Pharming Group N.V.'s filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.